Oruka Therapeutics
ORKA
12 hedge funds and large institutions have $1.2M invested in Oruka Therapeutics in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
32% more capital invested
Capital invested by funds: $910K → $1.2M (+$294K)
0.13% more ownership
Funds ownership: 0.97% → 1.11% (+0.13%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$227K |
| 2 |
JP Morgan Chase
New York
|
+$51.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$16.3K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.8K |
| 5 |
FMP
Financial Management Professionals
Austin,
Texas
|
+$64 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$75K |
| 2 |
QT
Quantamental Technologies
White Plains,
New York
|
-$13K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $814K | +$227K | +3,540 | +42% |
|
|
TCM
2
Tekla Capital Management
Boston,
Massachusetts
| $206K | – | – | – |
|
3
Acadian Asset Management
Boston,
Massachusetts
| $99K | – | – | – |
|
|
4
JP Morgan Chase
New York
| $55K | +$51.7K | +807 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $17K | +$16.3K | +255 | New |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $12K | +$11.8K | +185 | New |
|
7
Morgan Stanley
New York
| $1K | – | – | – |
|
|
ARTA
8
A.R.T. Advisors
New York
| – | -$75K | -1,168 | Closed |
|
|
QT
9
Quantamental Technologies
White Plains,
New York
| – | -$13K | -201 | Closed |
|
|
10
Victory Capital Management
San Antonio,
Texas
| – | -$1K | -20 | Closed |
|
|
FMP
11
Financial Management Professionals
Austin,
Texas
| – | +$64 | +1 | New |
|
ORKA Hedge Fund Activity: Q4 2019 in Review
12 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2019, worth a combined $1.2M — up 32% from $910K a quarter earlier.
Fund positioning in ORKA was balanced in Q4 2019: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $227K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $75K sold.
- 12 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $1.2M of Oruka Therapeutics stock for Q4 2019, up 32% quarter-over-quarter.
- 4 funds opened new Oruka Therapeutics positions in Q4 2019 and 4 closed out, a net change of 0 holders.
- The largest Oruka Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $227K added.
- The largest Oruka Therapeutics seller in Q4 2019 was A.R.T. Advisors, an estimated $75K sold.
Based on aggregated 13F filings for Q4 2019.